High Potency API Contract Manufacturing Value to reach US$ 8 Billion by 2032 | Oncology to account for over 60% Applications | FMI

A recently published study by FMI expects the global high potency API contract manufacturing market to augment at a 7% CAGR from 2022 to 2032. By the end of the said assessment period, a valuation of US$ 8 Billion is expected for the market.

Rising breakthroughs in high potency API (HPAPI) manufacturing technologies, combined with the quest for more effective drugs to improve patient outcomes, have significantly increased the number of HPAPIs in development pipelines, accelerating industry growth. Furthermore, a rising tendency in outsourcing operations due to greater risk management, lower costs, and the availability of modern ways to HPAPI controls has fueled growth.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15786

From 2017 to 2021, the industry experienced noteworthy growth, registering a value CAGR of 5% and closing at US$ 6.5 Billion. The sector is seeing profitable expansion, and suppliers are quickly investing in new facilities and expanding their R&D laboratories. Piramal Pharm Solutions, for example, plans to expand its API and HPAPI research and manufacturing facilities in Michigan with increased capacity and additional capabilities in December 2020. To fulfill predicted demand, which included prospective possibilities, the corporation spent US$ 32 million in the plant. HPAPI regulatory oversight has grown stronger over time.

Key Takeaways from the Market Study

• FMI projects the global high potency API Contract Manufacturing market to expand at a 7% value CAGR by 2032
• The global High Potency API Contract Manufacturing market is estimated at a market value of US$ 8 Billion
• The global high potency API contract manufacturing market is expected to garner a market value of US$ 16 Billion
• By application, oncology to experience major HPAPI contract manufacturing activities, yielding 63% of global revenue

“Demand for contract manufacturing of HPAPIs has expanded dramatically in recent years, and is one of the primary drivers of the global HPAPI market, owing to a rising number of prospective phase 3 drug candidates.”Says an analyst at FMI

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15786

Market Competition

Piramal Pharma Solutions, Lonza, Catalent, Inc., VxP Pharma, Inc., Pfizer CentreOne, Gentec Pharmaceutical Group, AbbVie, Aurigene Pharmaceutical Services Ltd., CordenPharma International and Curia Global, Inc., are some prominent High Potency API Contract Manufacturing manufacturers.

• In June 2021, Lonza, for example, spent USD 21.5 billion in its Nansha, China, plant to enhance its API development and manufacturing capacity. Three 1,000 L GMP trains totalling 12 cu. ft. of reactor volume m. Additional expenditures will be made, as well as new research and GMP facilities capable of creating small-scale batches of highly effective APIs.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the global automotive axle market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Product Type (Innovative and Generic), Synthesis (Synthetic and Biotech), Application (Oncology, Hormonal Disorders, Glaucoma and Others), Dosage Form (Injectable, Oral Solids, Creams and Others), across five major regions (North America, Latin America, Europe, Asia Pacific, South Asia, East Asia, Oceania and Middle East & Africa).

Request Report Methodology@ https://www.futuremarketinsights.com/request-report-methodology/rep-gb-15786

Key Segments Profiled in the High Potency API Contract Manufacturing Market Industry Survey

High Potency API Contract Manufacturing Market by Product Type:

• Innovative
• Generic

High Potency API Contract Manufacturing Market by Synthesis:

• Synthetic
• Biotech

High Potency API Contract Manufacturing Market by Application:

• Oncology
• Hormonal Disorders
• Glaucoma
• Others

High Potency API Contract Manufacturing Market by Dosage Form:

• Injectable
• Oral Solids
• Creams
• Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs